公开(公告)号：US20100172994A1

公开(公告)日：2010-07-08

申请号：US12445299

申请日：2007-11-23

Applicant: Wolfgang M. Sigmund ,  Yi-Yang Tsai ,  Ioannis Constantinidis ,  Jenny Dorley ,  Jose Antonio Oca-Cossio ,  Carol Ann Sweeney ,  Nicholas Edward Simpson ,  Mark A. Atkinson

Inventor： Wolfgang M. Sigmund ,  Yi-Yang Tsai ,  Ioannis Constantinidis ,  Jenny Dorley ,  Jose Antonio Oca-Cossio ,  Carol Ann Sweeney ,  Nicholas Edward Simpson ,  Mark A. Atkinson

IPC: A61K9/14 ,  A61K35/12 ,  A61K33/24

CPC classification number: C12N5/00 ,  A01N1/02 ,  A01N1/0226 ,  A61K9/5115 ,  A61K33/24 ,  A61K33/245 ,  A61K33/30 ,  C12N2531/00 ,  C12N2533/14 ,  C12N2533/20

Abstract: The present invention concerns metal oxide semiconductor nanoparticles with free radical scavenging activity, compositions comprising such nanoparticles, methods for their use, and methods for their production. In one aspect, the invention concerns a method for enhancing the survival or viability of transplanted cells, comprising administering an effective amount of metal oxide semiconductor nanoparticles to a target anatomical site of a subject before, during, or after administration of transplant cells to the subject. Preferably, the metal oxide nanoparticle is a cerium oxide (ceria) nanoparticle.

Abstract translation: 本发明涉及具有自由基清除活性的金属氧化物半导体纳米颗粒，包含这种纳米颗粒的组合物，其使用方法及其制备方法。 一方面，本发明涉及一种用于增强移植细胞的存活或存活力的方法，其包括在向受试者施用移植细胞之前，期间或之后向受试者的靶解剖部位施用有效量的金属氧化物半导体纳米颗粒 。 优选地，金属氧化物纳米颗粒是氧化铈（二氧化铈）纳米颗粒。

公开(公告)号：US20130023823A1

公开(公告)日：2013-01-24

申请号：US13583648

申请日：2011-03-10

Applicant: Nicholas Edward Simpson ,  Mark John Beveridge ,  Nelly Aline Volland

Inventor： Nicholas Edward Simpson ,  Mark John Beveridge ,  Nelly Aline Volland

IPC: A61M31/00 ,  B29C67/24

CPC classification number: A61K9/0024 ,  A61K9/5036 ,  A61K35/12 ,  A61K38/00 ,  C12N11/10

Abstract: The subject invention pertains to an implantable therapeutic device for treating diabetes and methods of making. Upon implantation, the present device secretes insulin in response to blood glucose levels, exquisitely regulates blood glucose levels, reduces hyperglycemia, and includes β-cell regeneration in the host. It is useful for treating or ameliorating diabetes or diabetic conditions of a subject, including but not limited to, type 1 diabetes mellitus, hyperglycemia, impaired glucose tolerance, insulin deficiency, elevated glucose levels, and insulin resistance.

Abstract translation: 本发明涉及用于治疗糖尿病的可植入治疗装置和制备方法。 在植入后，本装置响应于血糖水平分泌胰岛素，精细调节血糖水平，降低高血糖，并且在宿主中包括细胞再生。 可用于治疗或改善受试者的糖尿病或糖尿病状况，包括但不限于1型糖尿病，高血糖症，葡萄糖耐量降低，胰岛素缺乏症，葡萄糖水平升高和胰岛素抵抗。